Crohn’s Disease: Diagnosis, Treatment, and Integrative Management

Getting diagnosed with Crohn’s disease changes the way you think about your body. A condition that can flare without warning, affect your energy as much as your gut, and require ongoing treatment decisions is a lot to take in. If you are newly diagnosed, trying to understand your options, or looking for ways to complement your current treatment, this guide is for you.

Crohn’s disease is not something you caused, and it is not something you can simply fix with diet or willpower. But there is a lot you can do, alongside your gastroenterologist, to manage it effectively, reduce flares, and protect your long-term health. The treatment options today are dramatically better than they were even ten years ago.

This article covers what Crohn’s is, how it works at the biological level, how it is diagnosed, the full range of conventional and integrative treatments, common complications, and practical guidance for living with this condition.

What Is Crohn’s Disease?

Crohn’s disease is one of the two main forms of inflammatory bowel disease (IBD), the other being ulcerative colitis (UC). It is a chronic condition in which the immune system attacks the lining of the gastrointestinal (GI) tract, causing inflammation, ulceration, and tissue damage [1].

Unlike UC, which is limited to the colon and rectum and affects only the mucosal surface, Crohn’s can affect any part of the GI tract and involves full-thickness (transmural) inflammation that penetrates through all layers of the intestinal wall. This transmural nature is what makes Crohn’s prone to complications like strictures (narrowing), fistulas (abnormal tunnels between organs), and abscesses [1].

The most common sites of involvement are the terminal ileum (the end of the small intestine) and the colon, but Crohn’s can also affect the mouth, esophagus, stomach, and perianal area. The inflammation is often patchy, with diseased segments separated by normal-appearing bowel (called “skip lesions”).

Crohn’s vs. Ulcerative Colitis

About 5 to 15 percent of IBD cases are classified as “indeterminate colitis” because they share features of both conditions and cannot be definitively categorized [1].

What Causes Crohn’s Disease?

Crohn’s is not caused by any single factor. It results from a combination of genetic susceptibility, immune dysregulation, gut microbiome disruption, and environmental triggers. Researchers describe it as a disease where the immune system mounts an inappropriate, sustained inflammatory response to the gut’s microbial environment in genetically predisposed individuals [2].

Genetic Predisposition

More than 200 genetic loci have been associated with IBD risk. The most well-known is the NOD2/CARD15 gene, involved in innate immune recognition of bacterial components. Having a first-degree relative with Crohn’s increases your risk by 5 to 20 times, but genetics alone do not determine whether you develop the disease. Twin studies show a concordance rate of about 35 to 50 percent in identical twins [2].

Immune Dysregulation

In Crohn’s, the mucosal immune system fails to maintain tolerance to commensal gut bacteria. This triggers a chronic inflammatory cascade dominated by Th1 and Th17 immune responses, with excessive production of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-alpha), interleukin-12, interleukin-23, and interleukin-6 [3].

The inflammatory response becomes self-perpetuating. Damaged intestinal epithelium allows more bacterial products to cross the mucosal barrier, which triggers more immune activation, which causes more damage. Breaking this cycle is the central goal of Crohn’s treatment.

The Gut Microbiome

Patients with Crohn’s have measurably different gut microbiomes compared to healthy individuals. There is typically reduced microbial diversity, decreased levels of protective bacteria (particularly Faecalibacterium prausnitzii and other butyrate producers), and increased levels of potentially pathogenic bacteria like adherent-invasive E. coli (AIEC) [4].

Whether dysbiosis is a cause or consequence of Crohn’s (or both) remains an active area of research [4].

Environmental Triggers

The incidence of Crohn’s has risen dramatically in industrialized nations and is now increasing in developing countries as they adopt Western lifestyles. Environmental factors associated with increased risk include:

• Smoking: The strongest modifiable risk factor. Smoking doubles the risk of Crohn’s and worsens disease course (interestingly, it is protective against UC) [5]
• Antibiotics: Early-life antibiotic exposure is associated with increased IBD risk, likely through microbiome disruption [4]
• Diet: Western diets high in processed food, refined sugar, and low in fiber are associated with increased risk [5]
• NSAIDs: Can trigger flares in people with established IBD
• Stress: Does not cause Crohn’s but can trigger flares and worsen symptom severity

Symptoms of Crohn’s Disease

Crohn’s symptoms vary widely depending on which part of the GI tract is affected, the severity of inflammation, and whether complications have developed. The disease typically follows a relapsing-remitting pattern, with periods of active inflammation (flares) alternating with periods of relative quiet (remission).

GI Symptoms

• Abdominal pain: Often crampy, in the lower right abdomen (reflecting ileal involvement), worse after eating
• Diarrhea: Frequently watery, sometimes with visible blood or mucus
• Urgency and frequency: Feeling the need to use the bathroom frequently and urgently
• Nausea and vomiting: Especially with stricturing disease that causes partial obstruction
• Mouth sores: Aphthous ulcers are common
• Perianal disease: Fistulas, abscesses, skin tags, and fissures around the anus (affects up to 40 percent of Crohn’s patients)

Systemic Symptoms

• Fatigue: Often the most debilitating symptom, caused by inflammation, anemia, malnutrition, and disrupted sleep
• Weight loss: From reduced intake, malabsorption, and increased metabolic demands of chronic inflammation
• Fever: Low-grade fevers during flares
• Growth delay: In children and adolescents with Crohn’s

Extraintestinal Manifestations

Crohn’s is a systemic inflammatory condition, not just a gut disease. Up to 40 percent of patients develop manifestations outside the GI tract [6]:

• Joints: Peripheral arthritis, sacroiliitis, ankylosing spondylitis
• Skin: Erythema nodosum (tender red nodules), pyoderma gangrenosum (deep ulcers)
• Eyes: Uveitis, episcleritis
• Liver/bile ducts: Primary sclerosing cholangitis (more common in UC)
• Bones: Osteoporosis from chronic inflammation, malabsorption, and corticosteroid use
• Blood: Anemia (from iron deficiency, B12 deficiency, or chronic disease), venous thromboembolism (IBD patients have a 2 to 3 times higher risk of blood clots)

Diagnosis

There is no single test that confirms Crohn’s disease. Diagnosis is based on a combination of clinical presentation, endoscopic findings, histology (biopsy results), imaging, and laboratory tests [7].

Colonoscopy with Biopsies

Ileocolonoscopy (colonoscopy that includes examination of the terminal ileum) is the primary diagnostic tool. Endoscopic findings in Crohn’s include aphthous ulcers, deep serpentine or linear ulcers, a “cobblestone” mucosal pattern, skip lesions, and strictures. Biopsies showing chronic inflammation, granulomas (present in about 30 percent of cases), and architectural distortion support the diagnosis [7].

Imaging

MR enterography (MRE) or CT enterography is used to evaluate the small bowel, which is beyond the reach of standard colonoscopy. MRE is preferred because it avoids radiation exposure and provides excellent detail of bowel wall inflammation, strictures, fistulas, and abscesses. Pelvic MRI is the standard for evaluating perianal fistulas [7].

Laboratory Tests

• C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR): Markers of systemic inflammation; elevated during active disease but not specific to Crohn’s
• Complete blood count: May show anemia, elevated white blood cell count, and elevated platelets during active inflammation
• Albumin: Low levels indicate malnutrition and/or severe inflammation
• Iron studies, vitamin B12, folate, vitamin D: Assess for nutritional deficiencies common in Crohn’s

Fecal Calprotectin

Fecal calprotectin is a protein released by neutrophils in inflamed intestinal tissue. It is a highly sensitive marker of intestinal inflammation and is increasingly used for diagnosis, monitoring disease activity, predicting relapse, and distinguishing IBD from irritable bowel syndrome (IBS). A level above 250 micrograms per gram strongly suggests active intestinal inflammation [8].

Calprotectin is non-invasive (it just requires a stool sample) and is becoming a cornerstone of Crohn’s monitoring, allowing gastroenterologists to detect subclinical inflammation before symptoms return.

Conventional Treatments

The goals of Crohn’s treatment have evolved significantly. The current standard is not just symptom control but mucosal healing, meaning resolution of visible inflammation on endoscopy. Achieving mucosal healing is associated with fewer hospitalizations, fewer surgeries, and better long-term outcomes [9].

5-Aminosalicylates (5-ASAs)

Mesalamine (Asacol, Pentasa, Lialda) and sulfasalazine are mainstays of UC treatment but have limited efficacy in Crohn’s disease. They may have a role in mild Crohn’s colitis but are generally not recommended for small bowel disease or moderate-to-severe Crohn’s. Many gastroenterologists have moved away from 5-ASAs in Crohn’s in favor of more effective therapies [9].

Corticosteroids

Prednisone, prednisolone, and budesonide are effective at inducing remission during acute flares but are not appropriate for long-term maintenance. They do not promote mucosal healing, and chronic use causes serious side effects: osteoporosis, diabetes, adrenal suppression, cataracts, increased infection risk, mood changes, and weight gain [9].

Budesonide (Entocort, Uceris) is a topically acting corticosteroid with fewer systemic side effects and is preferred for mild-to-moderate ileal or right-sided colonic Crohn’s. The goal is always to get off steroids as quickly as possible, using them as a bridge to steroid-sparing maintenance therapy.

Immunomodulators

Thiopurines (azathioprine, 6-mercaptopurine) suppress the immune system by inhibiting purine synthesis. They are effective for maintenance of remission but take 8 to 12 weeks to reach full effect. Side effects include bone marrow suppression, liver toxicity, pancreatitis, and a small increased risk of lymphoma. TPMT or NUDT15 enzyme testing before starting helps identify patients at risk for severe toxicity [10].

Methotrexate is an alternative immunomodulator, given as a weekly injection or oral dose. It is effective for both induction and maintenance of remission in Crohn’s and is often used in patients who cannot tolerate thiopurines. Folic acid supplementation is given alongside to reduce side effects. Methotrexate is teratogenic and absolutely contraindicated in pregnancy [10].

Biologic Therapies

Biologics have transformed Crohn’s treatment. These are protein-based drugs that target specific components of the inflammatory cascade.

Anti-TNF agents (infliximab, adalimumab, certolizumab pegol) were the first biologics approved for Crohn’s and remain widely used. They block TNF-alpha, a key pro-inflammatory cytokine. Anti-TNF therapy achieves clinical remission in approximately 30 to 40 percent of patients at one year and mucosal healing in about 30 percent. Combination therapy with an immunomodulator (typically azathioprine) improves efficacy and reduces the formation of anti-drug antibodies [11].

Vedolizumab (Entyvio) is a gut-selective integrin inhibitor that blocks lymphocyte trafficking to the intestine. Because it acts locally in the gut rather than suppressing the whole immune system, it has a favorable safety profile. It is particularly useful in patients who have failed anti-TNF therapy or who have concerns about systemic immunosuppression [12].

Ustekinumab (Stelara) blocks interleukin-12 and interleukin-23, two cytokines central to the Th1 and Th17 immune responses that drive Crohn’s inflammation. It is given as an initial IV loading dose followed by subcutaneous maintenance injections every 8 weeks. It has shown efficacy in both anti-TNF-naive and anti-TNF-experienced patients [12].

Risankizumab (Skyrizi) is a newer IL-23 inhibitor (blocking only the p19 subunit, unlike ustekinumab which blocks both IL-12 and IL-23). Clinical trials have shown strong efficacy for both induction and maintenance of remission in Crohn’s, and it is increasingly being positioned as a first-line biologic option [12].

JAK Inhibitors

Janus kinase (JAK) inhibitors are small-molecule oral drugs that block intracellular signaling pathways involved in inflammation. Upadacitinib (Rinvoq) is approved for moderate-to-severe Crohn’s disease in patients who have had an inadequate response to other therapies. JAK inhibitors have the advantage of oral administration and rapid onset but carry risks including increased infection, herpes zoster reactivation, and potential cardiovascular and malignancy concerns identified in rheumatology studies [13].

Surgery

Up to 50 percent of Crohn’s patients will require at least one surgery within 10 years of diagnosis, despite improvements in medical therapy. Surgery does not cure Crohn’s (unlike UC, where colectomy is curative). Post-surgical recurrence rates are high without preventive medical therapy [14].

Common surgical indications include strictures causing obstruction, fistulas or abscesses not responding to medical therapy, perforation, and medically refractory disease. Strictureplasty (widening a narrowed segment without removing it) is preferred over resection when possible to preserve bowel length.

Endoscopic recurrence occurs in up to 70 percent of patients within one year of surgery. Starting biologic therapy within 4 weeks of surgery significantly reduces recurrence risk [14].

Integrative Approaches

Integrative therapies for Crohn’s should complement, not replace, conventional treatment. The evidence base varies from strong (dietary interventions, vitamin D) to promising but preliminary (curcumin, LDN). Always discuss these with your gastroenterologist before starting, particularly if you are on immunosuppressive therapy.

Diet

Diet plays a significant role in Crohn’s, though the optimal approach varies by individual. No single diet works for everyone, but several dietary strategies have evidence behind them.

Exclusive Enteral Nutrition (EEN): A liquid formula-only diet for 6 to 8 weeks is as effective as corticosteroids for inducing remission in pediatric Crohn’s and has good evidence in adults. It reduces intestinal inflammation, promotes mucosal healing, and alters the microbiome. It is the first-line induction therapy for pediatric Crohn’s in many countries [15].

Crohn’s Disease Exclusion Diet (CDED): Developed by Dr. Arie Levine, this is a whole-food-based diet that excludes components thought to promote intestinal inflammation (emulsifiers, processed foods, certain additives) while including foods that support a healthy microbiome. It is used with partial enteral nutrition and has shown efficacy in clinical trials for inducing remission [15].

Specific Carbohydrate Diet (SCD): The SCD eliminates complex carbohydrates, processed foods, and refined sugars, theorizing that undigested carbohydrates feed harmful bacteria. Observational data and small studies show clinical improvement in some patients, though large randomized trials are lacking [15].

Mediterranean Diet: High in fruits, vegetables, whole grains, olive oil, fish, and legumes, with limited red meat and processed food. It is anti-inflammatory by nature, has the best long-term adherence data of any dietary pattern, and is associated with reduced IBD risk in population studies [15].

Omega-3 Fatty Acids

Omega-3s from fish oil have anti-inflammatory properties and have been studied in IBD. Results are mixed. Cochrane reviews found insufficient evidence to recommend omega-3s for maintaining remission in Crohn’s, but some smaller studies support their use as an adjunct at higher doses (2 to 4 grams of EPA/DHA daily). They are generally safe and may provide benefit even if not sufficient alone [16].

Probiotics

Probiotic evidence in Crohn’s is weaker than in UC or pouchitis. No probiotic strain has shown consistent benefit for inducing or maintaining remission in Crohn’s in high-quality trials, though Saccharomyces boulardii and certain Lactobacillus strains have shown modest benefits in some studies. A single probiotic supplement is unlikely to correct the widespread dysbiosis present in active disease [4].

Vitamin D

Vitamin D deficiency is extremely common in Crohn’s patients (up to 60 to 70 percent), driven by malabsorption, reduced sun exposure during illness, and chronic inflammation. Beyond bone health, vitamin D plays a role in immune regulation, intestinal barrier function, and antimicrobial peptide production [17].

Low vitamin D levels are associated with more active disease, higher surgery rates, and increased hospitalization. A randomized trial by Jorgensen et al. found that vitamin D supplementation (1,200 IU daily) reduced the relapse rate in Crohn’s patients in remission from 29 percent to 13 percent [17].

Most IBD experts recommend maintaining vitamin D levels above 30 to 40 ng/mL, with supplementation doses of 2,000 to 5,000 IU daily commonly needed to reach target levels in Crohn’s patients.

Curcumin

Curcumin, the active compound in turmeric, has potent anti-inflammatory and antioxidant properties. It inhibits NF-kB, a master regulator of inflammatory gene expression. A randomized controlled trial by Lang et al. (2015) found that curcumin added to mesalamine therapy significantly improved clinical and endoscopic outcomes in UC. Data in Crohn’s is more limited but promising [18].

Bioavailability is a challenge with standard turmeric supplements. Formulations that enhance absorption (using piperine, liposomal delivery, or phytosome technology) are preferred. Doses in studies typically range from 1 to 3 grams of curcumin daily. Curcumin can interact with blood thinners and should be used with caution in patients with gallbladder disease.

Low-Dose Naltrexone (LDN)

LDN (typically 1.5 to 4.5 mg at bedtime) has shown intriguing results in small Crohn’s studies. A pilot trial by Smith et al. found that LDN (4.5 mg nightly) produced clinical response in 89 percent and remission in 67 percent of patients with active Crohn’s, with endoscopic improvement in many [19]. The proposed mechanism involves upregulation of endogenous opioid signaling, which modulates immune function and intestinal barrier integrity.

While these results are encouraging, the trials have been small and the evidence is not yet sufficient for mainstream guideline recommendations. LDN is inexpensive, well-tolerated, and available from compounding pharmacies. Some gastroenterologists are willing to prescribe it as an adjunct to standard therapy.

Stress Management

Stress does not cause Crohn’s, but it is a well-documented trigger for flares. The gut-brain axis is bidirectional: intestinal inflammation affects brain function (contributing to anxiety, depression, and fatigue), and psychological stress affects intestinal inflammation through cortisol, autonomic nervous system activation, and altered gut permeability [20].

Evidence-based stress management strategies for IBD include cognitive behavioral therapy, mindfulness-based stress reduction, gut-directed hypnotherapy, regular exercise, and adequate sleep. A trial by Mikocka-Walus et al. found that CBT reduced anxiety and depression and improved quality of life in IBD patients [20].

Complications

Understanding potential complications is important for monitoring and prevention.

Strictures

Chronic inflammation can lead to fibrosis and narrowing of the intestinal lumen. Strictures cause obstructive symptoms: crampy abdominal pain after eating, bloating, nausea, and vomiting. Some strictures respond to endoscopic balloon dilation; others require surgical resection or strictureplasty [14].

Fistulas

Transmural inflammation can create abnormal connections between the intestine and other structures: other bowel loops (enteroenteric), the bladder (enterovesical), the skin (enterocutaneous), or the vagina (rectovaginal). Perianal fistulas are the most common type. Treatment involves antibiotics (metronidazole, ciprofloxacin), anti-TNF therapy (infliximab has the best evidence for fistula healing), seton placement, and sometimes surgical repair [14].

Abscesses

Intra-abdominal or perianal abscesses occur when inflammation leads to walled-off collections of infection. They require drainage (percutaneous or surgical) and antibiotics before immunosuppressive therapy can be safely intensified.

Malnutrition

Malnutrition is common in Crohn’s, driven by reduced intake (pain with eating, restrictive diets), malabsorption (particularly with small bowel disease or after surgical resection), increased metabolic demands, and medication side effects. Key deficiencies to monitor include iron, vitamin B12, folate, vitamin D, zinc, and magnesium [6].

Cancer Risk

Long-standing Crohn’s colitis increases colorectal cancer risk, similar to UC. The risk increases with disease duration, extent of colonic involvement, severity of inflammation, and presence of primary sclerosing cholangitis. Surveillance colonoscopy is recommended starting 8 years after symptom onset in patients with at least one-third of the colon affected, with chromoendoscopy or random biopsies to detect dysplasia [21].

Small bowel adenocarcinoma is also slightly increased in Crohn’s patients with small bowel disease, though the absolute risk remains low.

Crohn’s and the Gut Microbiome

The relationship between Crohn’s and the gut microbiome is one of the most active areas of IBD research. Key findings include:

• Reduced diversity: Crohn’s patients consistently show lower microbial diversity than healthy controls
• Loss of beneficial species: Particularly Faecalibacterium prausnitzii, a major butyrate producer with anti-inflammatory properties. Low F. prausnitzii levels predict post-surgical recurrence [4]
• Increased pathobionts: Adherent-invasive E. coli (AIEC) is enriched in ileal Crohn’s tissue and can invade and replicate within macrophages, perpetuating inflammation
• Functional changes: Beyond species composition, the metabolic output of the Crohn’s microbiome is altered, with reduced short-chain fatty acid production and altered bile acid metabolism

Fecal microbiota transplantation (FMT) has shown success for recurrent C. difficile infection (which IBD patients are at high risk for), but results for treating Crohn’s itself have been inconsistent. The future likely involves more targeted microbiome-based therapies [4].

Mental Health and Crohn’s

The mental health burden of Crohn’s is significant and often undertreated. Anxiety and depression affect 30 to 40 percent of IBD patients during remission and even higher rates during active disease [20].

This is not just a psychological reaction to having a chronic illness. Inflammatory cytokines from the gut directly affect brain neurotransmitter systems (serotonin, dopamine), and 95 percent of the body’s serotonin is produced in the gut. Fatigue is the most common complaint among Crohn’s patients, even in remission. It is driven by subclinical inflammation, iron deficiency, sleep disruption, microbiome changes, and psychological distress [20].

Mental health care should be integrated into standard IBD management. Screening for anxiety and depression at regular visits, referral to a psychologist experienced with chronic illness, and antidepressant therapy when appropriate all improve outcomes. SSRIs and SNRIs are generally safe in Crohn’s [20].

Pregnancy and Crohn’s Disease

Women with Crohn’s can have healthy pregnancies, but planning is important. The key principles are:

• Conceive during remission: Active disease at conception is the strongest predictor of adverse pregnancy outcomes. Disease activity, not most medications, is the main risk to pregnancy [22]
• Most IBD medications are safe in pregnancy: Anti-TNF agents (infliximab, adalimumab, certolizumab), thiopurines, and mesalamine are generally continued through pregnancy. Certolizumab does not cross the placenta and may be preferred when starting a new biologic in women planning pregnancy
• Medications to stop before conception: Methotrexate (teratogenic, must be stopped at least 3 months before conception), tofacitinib/upadacitinib (insufficient safety data)
• Do not stop medications without discussing with your gastroenterologist: Disease flares during pregnancy are more dangerous than continuing most medications
• Delivery method: Vaginal delivery is generally safe unless there is active perianal disease, in which case cesarean section is recommended
• Breastfeeding: Most IBD medications are compatible with breastfeeding. Anti-TNF agents are large molecules that are minimally excreted in breast milk

Pre-conception counseling with both a gastroenterologist and a maternal-fetal medicine specialist is strongly recommended [22].

Finding a GI Specialist

Crohn’s is a complex condition that benefits from management by a gastroenterologist with specific expertise in IBD, not just general GI. Here is what to look for:

• IBD-focused practice: Gastroenterologists who devote a significant portion of their practice to IBD are more likely to be up to date on the latest treatments and to have experience with complex cases
• Multidisciplinary team: The best IBD centers have access to IBD-trained surgeons, nutritionists, mental health professionals, and advanced endoscopy
• Treat-to-target approach: Your gastroenterologist should be targeting mucosal healing (not just symptom relief), monitoring with objective markers (calprotectin, colonoscopy), and adjusting treatment proactively
• Academic medical centers: For complex or refractory Crohn’s, academic IBD centers offer access to clinical trials and multidisciplinary expertise
• The Crohn’s and Colitis Foundation (crohnscolitisfoundation.org) maintains a provider directory and offers patient support resources

Do not hesitate to seek a second opinion if your current treatment is not working. Crohn’s management has changed rapidly, and some patients remain on outdated regimens.

Related Reading

• Low-Dose Naltrexone (LDN): Uses, Dosing, and Evidence
• Gut Health: The Science of Your Microbiome
• Anti-Inflammatory Diet: What to Eat and Why
• Vitamin D: Dosing, Testing, and Health Effects
• Stress Management Techniques for Chronic Illness

Frequently Asked Questions

How effective are biologics like anti-TNF therapy for Crohn’s disease?

According to the guide, anti-TNF therapy achieves clinical remission in approximately 30 to 40 percent of patients at one year and mucosal healing in about 30 percent. Mucosal healing means resolution of visible inflammation on endoscopy, which is the goal of treatment rather than just symptom control. Other biologics covered include vedolizumab, ustekinumab, and risankizumab.

Can diet and supplements replace conventional Crohn’s medication?

No. The guide is explicit that integrative therapies for Crohn’s should complement, not replace, conventional treatment. It notes that no single diet works for everyone, and that Exclusive Enteral Nutrition is used as first-line induction therapy for pediatric Crohn’s in many countries. Approaches like the Crohn’s Disease Exclusion Diet, Specific Carbohydrate Diet, and Mediterranean Diet are presented as adjuncts.

Does vitamin D help prevent Crohn’s flares?

The guide cites a study where vitamin D supplementation at 1,200 IU daily reduced the relapse rate in patients in remission from 29 percent to 13 percent. Vitamin D deficiency is common in Crohn’s, affecting up to 60 to 70 percent of patients, and the guide suggests maintaining levels above 30 to 40 ng/mL. Typical supplementation ranges from 2,000 to 5,000 IU daily.

What does the evidence show for low-dose naltrexone (LDN)?

A pilot trial referenced in the guide reported an 89 percent clinical response and 67 percent remission, and LDN is described as inexpensive and well-tolerated at 1.5 to 4.5 mg at bedtime. However, the guide cautions that these are small trials and the evidence is not yet sufficient for mainstream guideline recommendations. It should be considered alongside, not instead of, conventional care.

What are the main side effects of standard Crohn’s medications?

The guide lists specific risks by drug class. Chronic corticosteroid use can cause osteoporosis, diabetes, adrenal suppression, cataracts, infection risk, mood changes, and weight gain. Thiopurines carry risks of bone marrow suppression, liver toxicity, pancreatitis, and a small increased risk of lymphoma, while JAK inhibitors are linked to increased infection, herpes zoster reactivation, and potential cardiovascular and malignancy concerns. Vedolizumab is noted for its favorable safety profile.

Will I eventually need surgery for Crohn’s disease?

The guide states that up to 50 percent of Crohn’s patients will require at least one surgery within 10 years, with surgery indicated for strictures, fistulas, abscesses, perforation, or medically refractory disease. Post-surgical recurrence rates are high, with endoscopic recurrence in up to 70 percent of patients within one year. Starting biologic therapy within 4 weeks of surgery significantly reduces recurrence risk.

References

[1] Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741-1755. doi:10.1016/S0140-6736(16)31711-1

[2] Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47(9):979-986. doi:10.1038/ng.3359

[3] de Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13(1):13-27. doi:10.1038/nrgastro.2015.186

[4] Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14(10):573-584. doi:10.1038/nrgastro.2017.88

[5] Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205-217. doi:10.1038/nrgastro.2015.34

[6] Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239-254. doi:10.1093/ecco-jcc/jjv213

[7] Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi:10.1093/ecco-jcc/jjy113

[8] Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients. Am J Gastroenterol. 2015;110(6):802-819. doi:10.1038/ajg.2015.120

[9] Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4-22. doi:10.1093/ecco-jcc/jjz180

[10] Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):CD000067. doi:10.1002/14651858.CD000067.pub2

[11] Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383-1395. doi:10.1056/NEJMoa0904492

[12] Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of ustekinumab induction and maintenance therapy in patients with moderate-to-severe Crohn’s disease: results from the UNITI/IM-UNITI trials. Gastroenterology. 2016;152(5):S1308. Also: Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946-1960. doi:10.1056/NEJMoa1602773

[13] Sandborn WJ, D’Haens GR, Reinisch W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active Crohn’s disease: results from the U-EXCEL and U-EXCEED phase 3 trials. Lancet. 2023;401(10389):1616-1628. doi:10.1016/S0140-6736(23)00688-X

[14] Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis. 2017;11(2):135-149. doi:10.1093/ecco-jcc/jjw169

[15] Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2):440-450. doi:10.1053/j.gastro.2019.04.021

[16] Turner D, Shah PS, Steinhart AH, Zlotkin S, Griffiths AM. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): a systematic review and meta-analyses. Inflamm Bowel Dis. 2011;17(1):336-345. doi:10.1002/ibd.21374

[17] Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease, a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32(3):377-383. doi:10.1111/j.1365-2036.2010.04355.x

[18] Lang A, Salomon N, Wu JC, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13(8):1444-1449. doi:10.1016/j.cgh.2015.02.019

[19] Smith JP, Bingaman SI, Ruber F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Am J Gastroenterol. 2011;106(2):275-283. doi:10.1038/ajg.2010.351

[20] Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(3):752-762. doi:10.1097/MIB.0000000000000620

[21] Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008

[22] van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9(2):107-124. doi:10.1093/ecco-jcc/jju006